ASCO GI: Agent Shows Promise in Pancreatic Cancer

SAN FRANCISCO (MedPage Today) — A liposomal formulation of irinotecan (CPT-11) passed an early clinical test in metastatic pancreatic cancer, meeting survival and safety endpoints for continued evaluation.

Post a Comment

Comments are closed.